Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Four BNT162 SARS-CoV-2 Vaccines
NCT04380701Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BNT162a1, BNT162b1 and tozinameran in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by BioNTech SE. Primary endpoints: Number of Participants With Solicited Local Reactions at the Injection Site, Number of Participants With Solicited Systemic Reactions and 2 more. Started Apr 2020; status: completed.
02
Drugs
BNT162a1BNT162b1tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380701.